|
N30 Pharma Announces FDA Approval to Initiate Phase 1 Clinical Trial for First …
PR Newswire (press release) It is the lead product in N30 Pharma's portfolio of drugs which are designed to treat asthma, COPD and IBD. N6022 will initially be tested using intravenous … |
View full post on asthma – Google News